EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively. EMT inhibitor-2 inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes.
Emtricitabine, a potent nucleoside reverse transcriptase inhibitor, is employed for managing HIV infection. Emtricitabine S-oxide, also known as Emtricitabine sulfoxide, represents a significant degradation byproduct of Emtricitabine.